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Abstract 
Recently, considerable progress has been made in 
designing biomaterial surfaces which possess enhanced 
albumin affinity. Two derivatization methods for pro-
ducing albumin binding biomaterial surfaces, based on 
an albumin affinity dye, cibacron blue, have been devel-
oped. Both surface derivatization methods were found 
to enhance the binding of albumin to an implant grade 
polyetherurethane. Evaluations of the enhanced albumin 
affinity demonstrated the binding to be both selective 
and reversible. Surfaces having such enhanced albumin 
affinity were found to be minimally thrombogenic and to 
discourage the adhesion of bacteria which might other-
wise cause device-centered infections. We conclude that 
albumin affinity surfaces, such as these, may be useful 
in the design of non-thrombogenic and infection resistant 
biomaterials. 
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Introduction 
Thrombosis is a major complication affecting poly-
meric blood-contacting medical devices (Lindsay, 1980; 
Leininger et al., 1987). These devices tend to be 
thrombogenic due, in part, to the surface adsorption of 
a variety of plasma proteins which can initiate coagula-
tion and activate platelets (Zucker and Vroman, 1969; 
Kim et al., 1974; Absolom et al. , 1987; Collins et al., 
1987; Fukumura et al., 1987; Salzman et al. , 1987; 
Sevastianov, 1988; Ito and Imanishi, 1989). This pro-
coagulant activity of many polymeric devices prevents 
their use in vivo or greatly diminishes their useful life-
time. Besides being procoagulant, these same devices 
can also serve as foci for infection, promoted by the 
tendency of certain microorganisms to adhere to, and 
colonize, their surfaces (Christensen et al., 1982; Lowy 
and Hammer, 1983; Gower et al., 1986; Hogt et al., 
1986, 1987; Schmitt et al., 1986; Jansen et al., 1989). 
For these reasons, there is a real medical need to create 
polymeric materials which are less thrombogenic and 
less liable to harbor pathogenic bacteria. 
One potential solution to the problem of surface ad-
sorption of procoagulant proteins and cells on polymeric 
materials is based on the selective adsorption of albu-
min. Indeed, in some experimental systems, surfaces 
coated directly with albumin have demonstrated dimin-
ished adherence of cells and, especially, platelets (Zuck-
erand Vroman, 1969; Kimetal., 1974; Absolometal., 
1987). Unfortunately, thus far, there has been no fully 
effective way of creating polymeric materials with sur-
faces which selectively bind albumin in vivo. 
One prior promising attempt was based on the well-
known ability of albumin to bind free fatty acids; sur-
faces displaying straight-chain 16- or 18-carbon alkyl 
groups were made in hopes that this might enhance sur-
face albumin affinity (Munro et al., 1981). Indeed, the 
addition of alkyl chains did increase the surface affinity 
for albumin during brief incubations (Frautschi et al., 
1983; Eberhart et al., 1987; Pitt and Cooper, 1988) and 
improved thromboresistance in an acute canine ex vivo 
experiment (Grasel et al., 1987). However, these 
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materials are not entirely selective for albumin binding 
and may, due to the highly hydrophobic nature of the 
surface, encourage the subsequent denaturation of 
adsorbed protein (Andrade and Hlady, 1986). 
Our attempt to engineer polymeric surfaces with en-
hanced albumin affinity is based on the ability of albu-
min to bind a variety of triazine dyes such as cibacron 
blue. In fact, a commonly used technique for purifying 
albumin relies on this afftnity. The purification tech-
nique involves the passage of solutions containing albu-
min, e.g., plasma, over an affinity support matrix to 
which cibacron blue dye is covalently bound (Travis et 
al. , 1976). A variety of affmity support matrices in-
cluding agarose (Sigma Chern. Co., St. Louis, MO), 
Sephacryl® (Sigma), Sephadex (Sigma), Sepharose 
(Sigma), etc. have been used (Kopperschlager et al., 
1982). In our work, we have used a 2 million molecu-
lar weight dextran. We felt that dextran would act as an 
appropriate hydrophilic "spacer," thus preventing the 
close surface approach and consequent denaturation of 
bound albumin. We also anticipated that the dextran 
spacer would be highly stable in vivo due to the fact that 
mammals lack dextranase enzymes. Furthermore, ciba-
cron blue dye is quite stable at extreme pHs. Therefore, 
although the catabolism of this dye in vivo has not been 
characterized, we felt that it would likely resist degrada-
tion. We also predicted that polymeric materials dis-
playing "blue dextran" (dextran coupled with cibacron 
blue dye) would spontaneously, selectively and reversi-
bly bind albumin upon contact with blood and certain 
other body fluids. With this in mind, two methods were 
developed to incorporate blue dextran on the surface of 
polymeric materials. (1) The first employs a co-solva-
tion technique for incorporating blue dextran throughout 
a polyurethane. (2) The second method covalently 
attaches blue dextran to the surface of the polyurethane. 
The resultant polymeric materials from both derivatiza-
tion methods demonstrate an increase in albumin affini-
ty. This increase in albumin affinity confers a number 
of desirable properties, including increased thrombo-
resistance and decreased bacterial adherence. 
Materials and Methods 
Incorporation of blue dextran 
The co-solvation technique for incorporating blue 
dextran throughout a polyurethane has previously been 
described (Keogh et al., 1992). Briefly, 0.3 g of blue 
dextran (BD) (Sigma Chemical Co., St. Louis, MO) was 
dissolved in 1.5 m1 of deionized (Dl) water. This mix-
ture was then added to 20 g of N,N-dimethylacetamide 
(DMAC) (Fisher Scientific Co., Pittsburg, PA). To this 
blue dextran/solvent mixture, 1.0 g of raw 2363-55D 
(55D) Pellethane (Dow Chemical Co., Midland, Ml) 
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pellets, an implant grade polyetherurethane, was added. 
The resultant mixture was then shaken overnight to al-
low complete solvation of the polyurethane. The sol-
vated blue dextran/polyurethane mixture was then cast 
into film (0.3 mm thick) on Mylar® (Custom Coating 
and Laminating Corporation, Worcester, MA) release 
sheets or tubing (2 mm internal diameter, ID) on glass 
mandrels and dried overnight in a vacuum oven at 50°C 
to remove the solvent. 
The covalent attachment of blue dextran to the sur-
face of the polyurethane also has been previously de-
scribed (Keogh and Eaton, 1994). Briefly, raw pellet-
ized 55D was extruded into film (0.3 nun thick) using a 
RC 0625 Randcastle (Little Falls, NJ) vertical screw ex-
truder and into tubing (2 nun ID) using a Harrel (Nor-
walk, CT) horizontal screw extruder. No processing 
aids were added prior to extrusion. The film was then 
cut into 1 cm2 sample disks. Both tubing and sample 
disks were cleansed in reagent grade ethanol (Sigma) for 
at least two hours to remove most surface contamination, 
thoroughly rinsed in DI water and allowed to dry. Ex-
truded 55D samples were then placed into a surface 
grafting solution consisting of 11.2 M acrylamide 
(AAm) (Eastman Kodak Co., Rochester, NY), 1.1 M 
N-(3-aminopropyl)methacrylamide (APMA) (Eastman 
Kodak), 400 mM nitric acid (HN03) (Aldrich Chemical 
Co., Milwaukee, WI) and 40 mM ammonium cerium 
(IV) nitrate [(NH4hCe(N03)6] (Aldrich) in DI water. 
Grafting was allowed to proceed for 30 minutes before 
the samples were removed and thoroughly rinsed in DI 
water to remove any residual monomer. 
Sodium metaperiodate (Nal04) (Sigma) oxidized 
dextran (Sigma), 2 million molecular weight, was then 
coupled through Schiffs base formation to the AArn! 
APMA grafted polyurethane surface. Dextran was oxi-
dized by placing 5.0 g of dextran in 100 ml DI water 
containing 5.0 mg Nal04, incubating in the dark for 2 
hours and then dialyzing against DI water for 24 hours 
to remove any residual periodate. The AAm/ APMA-
grafted polyurethane was placed in the oxidized dextran 
solution at 25°C and stirred. After 1 hour, 3 mg/ml 
sodium cyanoborohydride (NaCNBH3) (Sigma) was 
added, and the samples were incubated with stirring for 
2 hours at 25°C, thus stabilizing the Schiffs bases 
which had formed between the aldehydes of oxidized 
dextran and the amino groups of APMA. The samples 
were then removed and rinsed thoroughly in DI water. 
Cibacron blue 3GA dye (Sigma) was then covalently 
coupled to the AAm/ APMA-dextran derivatized polyure-
thane by incubating the derivatized polyurethane for 6 
hours in a dye solution containing 6.5 mM cibacron blue 
dye, 0.3 M NaCl (Sigma) and 0.7 M NaHC03 (Sigma) 
in DI water. The blue dextran surface-derivatized poly-
urethane was then rinsed thoroughly in DI water. 
Albumin affinity biomaterial surfaces 
Surface characterization 
The extent of blue dextran derivatization on polyure-
thane surfaces was assessed with several techniques. 
Fourier transform infrared spectroscopy with attenuated 
total reflectance optics (FTIR/ ATR) was performed with 
a SPC 3200 Bio-Rad (Cambridge, MA) spectrometer 
and a 45° germanium ATR crystal. Electron spectros-
copy for chemical analysis (ESCA) was performed on 
material surfaces using a 5400 Perkin-Elmer Physical 
Electronics (Eden Prairie, MN) ESCA spectrometer. 
Scanning electron microscopy (SEM) was performed on 
material surfaces following mounting and sputter-coating 
with gold. The samples were viewed using a JSM-35CF 
JEOL (Peabody, MA) SEM. 
Albumin affinity detenninations 
The extent of surface binding of albumin to blue 
dextran bulk-derivatized 55D sample disks (1 cm2) 
(hereafter, "bulk-derivatized 55D") and blue dextran 
surface-derivatized 55D sample disks (1 cm2) (hereafter, 
"surface-derivatized 55D") was estimated by incubation 
of derivatized samples in solutions containing radiola-
beled human albumin. Sample disks ofbulk-derivatized, 
surface-derivatized and non-derivatized 55D were first 
rinsed in isotonic phosphate buffered saline (PBS), pH 
7 .4, at 25°C for 15 minutes prior to incubation for 1 
hour at 25°C in 1251-labeled human albumin diluted in 
PBS (final concentration = 15.7 J.tg/ml; specific activity 
= 8.5 14Ci/mg protein) (Mallinkrodt, St. Louis, MO). 
Following incubation, the samples were thoroughly 
rinsed with PBS, placed in scintillant and then counted 
in a scintillation counter. 
The selectivity of the binding of albumin by bulk-
derivatized, surface-derivatized and non-derivatized 55D 
in the presence of 1251-labeled fibrinogen (15. 7 J.tg/ml; 
specific activity = 115 14Ci/mg protein) (Amersham, Ar-
lington Heights, IL) was determined using 1: 1 mixtures 
of albumin and fibrinogen. Fibrinogen was used as a 
competitive protein since it is well known that fibrinogen 
readily adsorbs to most medical device surfaces and be-
cause surfaces with adsorbed fibrinogen tend to be 
thrombogenic (Zucker and Vroman, 1969; Kim and Lee, 
1979; Chinn et al., 1991). Disks of bulk-derivatized, 
surface-derivatized and non-derivatized 55D were ex-
posed to a 1:1 by weight 1251-labeled albumin/unlabeled 
fibrinogen or 1251-labeled fibrinogen/unlabeled albumin 
mixture (final protein concentration, 15.7 J.tg/ml) for 1 
hour at 25°C. In making these mixtures, the albumin 
added to 1251-labeled fibrinogen by the supplier was 
taken into account. The samples were then thoroughly 
rinsed with PBS, placed in scintillant and counted in a 
scintillation counter. 
Proteins that remain adherent to the surface of poly-
meric materials despite thorough washing in sodium do-
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decyl sulfate (SDS) are considered denatured and irre-
versibly bound (Bohnert and Horbett, 1986; Rapoza and 
Horbett, 1989; Chinn et al. , 1991, 1992). Therefore, 
the reversibility of albumin binding to blue dextran-
derivatized surfaces was determined by measuring the 
elutability of previously adsorbed protein using a 1% 
SDS (Sigma) wash. Disks of bulk-derivatized, surface-
derivatized and non-derivatized 55D were incubated for 
5 hours in 1251-labeled albumin (15.7 J.tg/ml) at 25°C. 
The samples were then rinsed with PBS and incubated in 
PBS alone or in a 1% SDS solution for 1 hour at 25°C. 
After incubation, the samples were rinsed in PBS, 
placed in scintillant and counted in a scintillation 
counter. 
Reversibility of albumin binding was also estimated 
by the release of 1251-labeled albumin by subsequent in-
cubation in solutions of unlabeled albumin. Again, bulk-
derivatized, surface-derivatized and non-derivatized 55D 
disks were incubated for 5 hours in 125!-labeled albumin 
(15.7 J.tglml) at 25°C. The samples were then rinsed in 
PBS followed by immersion in PBS containing 1 mg/ml 
unlabeled human serum albumin for 1 hour at 25°C. 
The extent of displacement of bound 1251-labeled albu-
min by free unlabeled albumin was then determined by 
scintillation counting of both disks and supernatants. 
Finally, the extent to which surface binding of albu-
min by blue dextran-derivatized polyurethane is mediated 
specifically by an association between the immobilized 
cibacron blue dye and albumin was determined by using 
solution-phase blue dextran to competitively elute bound 
albumin. Bulk-derivatized, surface-derivatized and non-
derivatized 55D disks were incubated in 1251-labeled 
albumin (15.7 J.tg/ml) for 5 hours at 25°C. The samples 
were then rinsed in PBS and incubated in PBS alone or 
in PBS containing soluble blue dextran (5 mg/ml) for 1 
hour at 25°C. Following incubation, the samples were 
rinsed in PBS, placed in scintillant and counted in a 
scintillation counter. 
Thromboresistance measurements 
As one indication of the tendency of blue dextran-
derivatized polyurethane to affect clotting of whole 
blood, limited studies using a Baumgartner (1973) appa-
ratus and a Chandler (1958) blood loop were performed. 
For investigations using the Baumgartner apparatus, ve-
nous blood was drawn from a human subject (who had 
not taken aspirin within the last two weeks) into a plastic 
vessel containing citrate. These studies were approved 
by the Committee on Research Involving Human Sub-
jects, University of Minnesota. The citrate-anticoagu-
lated blood, maintained at 3rc, was then pumped 
through the Baumgartner (1973) perfusion chamber con-
taining bulk-derivatized and non-derivatized 55D tubing 
samples (2 mm ID and 5 em in length). Blood flow was 
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maintained at a rate of 140 ml/min (shear rate of 800 
s-1) for five minutes. The samples were then removed, 
fixed and stained with Diff-Quik (Baxter Healthcare 
Corp., McGraw Park, IL) stain set. Adherent platelets 
were quantified using a light microscope (field size of 
3.7 X 10-J mm2). 
For investigations using a Chandler (1958) blood 
loop, venous blood was again drawn from a human sub-
ject into a plastic syringe containing no anticoagulant. 
One-milliliter aliquots of whole human blood were then 
delivered immediately into (1) a 12 mm x 75 mm glass 
test tube, (2) an ethanol-sterilized non-derivatized 550 
tubing sample (2 mm ID and 30 em in length) and (3) an 
ethanol-sterilized surface-derivatized 55D tubing sample 
(also 2 mm ID and 30 em in length). One end of each 
of the polyurethane tubes was looped around and con-
nected to the other end via an external silicone sleeve. 
The 1 m1 aliquot of whole blood was purposely not 
enough blood to fill the entire tube, thus forming an air-
blood interface which tends to accelerate the clotting of 
whole blood. The polyurethane tubes were then attached 
to a vertical circular plate and rotated at 9 rpm at 37 o C 
until the blood clotted. The glass test tube was gently 
tilted every 30 seconds at 37°C until the blood clotted. 
After 16 hours (the long incubation due to the fact 
that the blood within the surface-derivatized 55D tubing 
samples never clotted), the blood was expelled from the 
sample loops. The tubing samples were then vigorously 
rinsed in PBS and placed in 2.5% glutaraldehyde (Sig-
ma) solution overnight. Following mounting and sput-
ter-coating with gold, sample surfaces were examined 
with a JEOL JSM-35CF SEM for adherent thrombus. 
Bacterial adherence assay 
Bacterial adherence to implant surfaces is thought to 
be a major mechanism underlying the high frequency of 
device-associated infections. We, therefore, carried out 
limited bacterial adherence studies with bulk-derivatized, 
surface-derivatized and non-derivatized 55D samples 
using Staphylococcus (S.) epidermidis. S. epidermidis 
(an uncatalogued "slime"-producing clinical isolate ob-
tained from an infected catheter by the Microbiology 
Laboratory at the University of Minnesota) were grown 
overnight in Brain Heart Infusion broth (Difco Co., De-
troit, MI) in a shaking water bath at 37°C. The bacteria 
were then concentrated centrifugally and washed three 
times in isotonic saline solution and resuspended in ster-
ile Hanks' balanced salt solution to 1.05 x 109 cfu/ml. 
Bulk-derivatized, surface-derivatized and non-derivatized 
55D sample disks (1.0 cm2), both with and without 
preadsorption of albumin (15. 7 J.Lg!ml) for 4 hours at 
25°C, were immersed in this bacterial suspension with 
gentle mixing for 1 hour at 25°C. After incubation, the 
samples were thoroughly rinsed in sterile isotonic saline 
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Figure 1. Adsorption of 1251-labeled human albumin on 
non-derivatized 55D, bulk-derivatized 55D and surface-
derivatized 55D disks. Quadruplicate samples were in-
cubated in 125I-labeled albumin (15.7 1-1-g/ml) for 1 hour 
at 25°C and thoroughly rinsed in PBS. The surface as-
sociated 125!-labeled albumin was determined by scintil-
lation counting. Results are expressed as the mean total 
amount of albumin adsorbed/cm2 ± 1 standard devia-
tion , SD (p < 0.01 between non-derivatized and both 
derivatized samples, Student's t-test, two-tailed). 
solution and placed in 5 m1 of sterile saline solution. 
The samples were then gently sonicated at 20 W for 1 
minute to release adherent bacteria. This power setting 
was experimentally determined not to decrease the via-
bility of solution-phaseS. epidermidis. After sonication, 
the numbers of displaced bacteria were enumerated by 
pour-plating appropriate dilutions as previously described 
(Ma and Eaton, 1992). 
Results 
Surface characterization 
As reported earlier (Keogh, 1992; Keogh and Eaton, 
1994), the blue dextran bulk derivatization technique 
partially obscured the polyurethane surface as estimated 
with FTIR/ ATR and ESCA. In contrast, the blue dex-
tran surface derivatization technique completely obscured 
the polyurethane surface as estimated with FTIR/ ATR 
and ESCA, and the resultant surface coating had a thick-
ness of approximately 2 ~-tm. as estimated with SEM. 
Albumin affinity 
Blue dextran surface-derivatized 55D was found to 
bind approximately twice as much 1251-labeled albumin 
as did non-derivatized 55D and roughly 50% more than 
bulk-derivatized 55D (Fig. 1). This enhanced albumin 
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Figure 2. Relative adsorption of albumin and fibrinogen 
to non-derivatized 55D, bulk-derivatized 55D and sur-
face-derivatized 55D disks. Triplicate samples were in-
cubated in either a 1:1 by weight 125I-labeled albu-
min/fibrinogen or 125I-labeled fibrinogen/albumin mix-
ture (fmal protein concentration, 15.7 J.tg/rnl) for 1 hour 
at 25°C and thoroughly rinsed in PBS. The surface as-
sociated 1251-labeled albumin or 1251-labeled fibrinogen 
was determined by scintillation counting. Results are 
expressed as the mean percentage of total protein 
adsorbed ± 1 SD. 
Table 1. The number of platelets spontaneously adher-
ent to non-derivatized 55D tubing and bulk-derivatized 
55D tubing. Triplicate samples were placed in a Baum-
gartner apparatus and exposed to flowing citrate-anti-
coagulated whole human blood for 5 minutes at 37°C. 
Adherent platelets were quantified using light micros-
copy. Results are expressed as the mean number of 
platelets/mm2 ± 1 SD (20 fields of size 3. 7 X w-3 mm2; 
non-derivatized differs from bulk-derivatized 55D at 
p < 0.01, Student's t-test, two-tailed). 
Sample 
non-derivatized 55D 
bulk-derivatized 55D 
# Platelets/mm2 
23,000 ± 8,700 
81 ± 154 
binding appears to be selective. As shown in Figure 2, 
when non-derivatized 55D is incubated with equal 
proportions (weight/weight) of fibrinogen and albumin, 
bound fibrinogen predominates. However, similar 
experiments with blue dextran-derivatized surfaces 
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Figure 3. Percent elution of albumin previously bound 
to non-derivatized 55D, bulk-derivatized 55D and sur-
face-derivatized 55D disks by SDS, albumin or solution-
phase blue dextran. Triplicate samples were incubated 
in 1251-labeled albumin (15.7 J.tglrnl) for 5 hours at 25°C 
and thoroughly rinsed in PBS. The samples were then 
incubated for 1 hour at 25°C in a 1% SDS solution, a 
solution of 1 mg/rnl soluble unlabeled albumin or a solu-
tion of 5 mg/ml soluble blue dextran. The surface asso-
ciated 125!-labeled albumin was determined by scintilla-
tion counting. Results are expressed as the mean per-
centage of elutable albumin ± 1 SD (p < 0.01 non-de-
rivatized or both types of derivatized samples, Student's 
t-test, two-tailed). 
Table 2. Times at which 1 rnl of freshly shed whole 
human blood clotted in non-derivatized 55D tubing, sur-
face-derivatized 55D tubing and glass test tubes. Results 
shown are from a single experiment involving duplicate 
samples. These results are representative of three addi-
tional and independent experiments (all four blood sam-
ples from a single donor). Overall, for glass and non-
derivatized SSD, the time at which clotting occurred 
varied by no more than 10%. 
Sample Clotting Time 
glass test tube 5.75 minutes 
non-derivatized 55D 9.5 minutes 
surface-derivatized 55D > 16 hours 
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Figure 4. Light micrographs of the surfaces of (A) non-
derivatized 55D and (B) bulk-derivatized 55D after a 5 
minute exposure to flowing citrate-anticoagulated human 
blood at 3rc. Bars = 10 J.'m. 
reveale.d an albumin preference of almost 70% in the 
case of bulk-derivatized 55D, and over 95% in the case 
of surface-derivatized 55 D. Furthermore, less than 30% 
of the albumin bound to non-derivatized 55D was elut-
able by SDS, solution-phase blue dextran or albumin 
(Fig. 3). However, albumin binding to blue dextran-de-
rivatized surfaces was found to be much more reversible 
and ligand specific. As shown in Figure 3, at least 70% 
of the albumin which binds to bulk-derivatized 55D is 
released by SDS and appears to be ligand specific (i.e., 
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Figure 5. Scanning electron micrographs of the sur-
faces of (A) non-derivatized 55D and (B) surface-deriva-
tized 55D after a 16 hour exposure to flowing non-anti-
coagulated human blood at 37°C. Bars = 10 J.'ffi. 
is released by solution phase albumin and blue dextran). 
In the case of surface-derivatized 55D, more than 95% 
of the bound albumin appears to be bound reversibly to 
the surface incorporated blue dextran. 
Albumin affinity biomaterial surfaces 
Figure 6. Scanning electron micrographs of surfaces of 
(A) non-derivatized 55D and (B) surface-derivatized 
55D. Bars = 2 J.tm. 
Thromboresistance 
When tubing samples were studied under flow in a 
Baumgartner (1973) device, large numbers of platelets 
were found to adhere to non-derivatized 55D, whereas 
almost no detectable platelets were adherent to bulk-deri-
vatized 55D (Table 1). Importantly, the large numbers 
of platelets adherent to non-derivatized 55D were acti-
vated, as indicated by the spread pseudopodia of adher-
ent platelets (Fig. 4A). In contrast, the few platelets 
found on bulk-derivatized 55D were not activated by 
morphological criteria (Fig. 4B). 
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Figure 7. Bacterial adherence to albumin-coated non-
derivatized 55D, bulk-derivatized 55D and surface-deri-
vatized 55D disks. Triplicate samples were pre-incu-
bated in albumin (15. 7 J.'g/rnl) for 4 hours at 25°C. The 
samples were then incubated in a suspension of S. epi-
dermidis solution for 1 hour at 25°C. After incubation 
in the bacterial suspension, the samples were rinsed and 
sonicated. The bacteria displaced were then plated, in-
cubated and counted. Results are expressed as the mean 
number of cfu/cm2 ± 1 SD (p < 0.01 between all sam-
ples, Student's t-test, two-tailed) . 
The results in Table 2 indicate that surface-deri-
vatized 55D also has a profound inhibitory effect on the 
clotting of whole blood. In fact, non-anticoagulated ve-
nous blood clotted within 6 minutes in glass tubes, with-
in 9 to 11 minutes in non-derivatized 55D tubes, but did 
not clot even after 16 hours incubation in surface-deriva-
tized 55D tubing. Scanning electron micrographs of the 
tubing from the incubations reported in Table 2 revealed 
multiple thrombi and fibrin strands on the surface of the 
non-derivatized 55D (Fig. SA). In contrast, there was 
little or no cellular adhesion of any kind on the surface-
derivatized 55D (Fig. 5B). Note that the rugosities evi-
dent on the surface-derivatized 55D represent, in part, 
a drying artifact which may reveal areas of primary "nu-
cleation" of the eerie ion grafting of acrylamide to the 
surface of the polyurethane. These nucleation sites are 
more clearly evident when comparing clean surfaces of 
non-derivatized 55D (Fig. 6A) and surface-derivatized 
55D (Fig. 6B). 
Bacterial adherence 
Finally, as shown in Figure 7, the binding of S. 
epidermidis to bulk-derivatized 55D surfaces is more 
than 70% less than that to non-derivatized 55D surfaces 
when the surfaces were pre-incubated with albumin. 
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More strikingly, however, bacteria are almost complete-
ly incapable of adhering to the surfaces of surface-deri-
vatized SSD which has been pre-incubated with albumin. 
Discussion 
Thrombosis and infection are among the most fre-
quent iatrogenic problems associated with implantable 
and blood-contact medical devices. Especially in the 
case of devices made of polymeric elastomers, these ad-
verse effects may be initiated by rapid formation of a 
layer of adsorbed, apparently denatured, proteins on the 
surface. This chaotic array of adsorbed proteins may be 
thrombogenic. Furthermore, the adsorption of fibrino-
gen in particular has recently been shown responsible for 
the acute inflammatory effects of at least one type of im-
planted biomaterial (Tang and Eaton, 1993; Tang et al., 
1996). Finally, this layer of denatured host proteins 
may form a substratum, permitting the adherence and 
colonization of device surfaces by microorganisms. 
One technique for preventing the chaotic adsorption 
of proteins and cells on medical device surfaces is by 
way of an albumin coating. Numerous investigators 
have found that coating of a biomaterial surface with 
albumin "passivates" the surface by diminishing throm-
bosis, the adherence of pathogenic bacteria and, perhaps, 
the inflammatory response. Unfortunately, despite the 
fact that albumin is the predominant plasma protein, 
many other proteins typically have at least an equal 
affinity to the medical device surface. Therefore, selec-
tive coating of a medical device surface with albumin 
typically does not occur in vivo. Furthermore, direct 
attachment of albumin to the device surface can contrib-
ute to the aforementioned problems since irreversibly 
bound albumin eventually degrades. For these reasons, 
there have been some attempts to engineer medical de-
vice surfaces with enhanced albumin affinity. As de-
scribed earlier, one strategy was based on the well-
known ability of albumin to bind free fatty acids with 
high affinity. Unfortunately, these materials are not en-
tirely selective for albumin binding and may, due to the 
highly hydrophobic nature of the surface, even encour-
age the denaturation of adsorbed protein. 
Our work has been based on the premise that the 
development of effective and compatible blood-contact 
devices depends on creating surfaces which can regulate, 
without denaturing, the types and amounts of protein that 
adsorb on the surface. Therefore, we employed the con-
cept of affinity chromatography to produce biomaterial 
surfaces which selectively and reversibly bind albumin 
in vivo. One very effective affinity chromatography 
technique widely used for separating albumin from plas-
ma involves the use of cibacron blue dye (Travis et al., 
1976). In fact, albumin from most mammals will bind 
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tenaciously (Kd - w-7, dissociation constant derived 
from Scatchard plot) to immobilized cibacron blue dye 
(perhaps through a specific interaction with the bilirubin 
binding site on albumin) (Leatherbarrow and Dean, 
1980). While other proteins and, especially, adenine nu-
cleotide-dependent enzymes also bind to immobilized ci-
bacron blue dye, albumin is by far the predominant plas-
ma protein which binds this dye (Travis et al., 1976). 
Based on cibacron blue dye, two derivatization 
methods for producing albumin affinity biomaterial sur-
faces were developed. Evaluations of albumin affmity 
of polymeric materials incorporated with cibacron blue 
dye demonstrate that both methods produce surfaces 
which preferentially bind albumin even from mixtures 
containing equal amounts of both fibrinogen and albu-
min. Furthermore, albumin is bound to these surfaces 
by a ligand-affinity mechanism in as much as previously 
bound albumin is readily released by solution-phase al-
bumin or blue dextran. In addition, these cibacron blue 
derivatized materials have an unexpectedly potent anti-
thrombogenic character, retarding non-cellular clotting 
as well as platelet adherence. Finally, these hydrophilic 
albumin affinity surfaces discourage the adherence of po-
tentially pathogenic bacteria. We conclude that surfaces 
with similar characteristics may hold some promise for 
the development of less thrombogenic biomaterials which 
also are less liable to foster device-associated infections 
by adherent microorganisms. 
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Discussion with Reviewers 
C. Tsai: How long will the blue dextran last on the 
surface? 
Authors: As stated in the text, we felt the dextran 
spacer would be highly stable in vivo due to the fact that 
mammals lack dextranase enzymes. Also, since ciba-
cron blue dye is quite stable at extreme pHs and, al-
though the catabolism of this dye in vivo has not been 
characterized, we felt it would likely resist degradation. 
However, we have not carried out any long term implan-
tation studies to directly measure the time. 
C. Tsai: Do other plasma proteins, such as lgG, high 
molecular weight Kininogen (HMWK), Factor XII and 
complement proteins, which all can have a negative im-
pact on blood compatibility of foreign materials, bind to 
your surfaces? 
Authors: Unfortunately, the binding of purified plasma 
proteins such as lgG, HMWK, Factor XII and comple-
ment proteins has not been characterized. However, we 
earlier demonstrated that wher. blue dextran surface-
derivatized material was directly immersed in whole 
human plasma, very few other proteins aside from albu-
min could be detected electrophoretically following elu-
tion from the material surface (Keogh and Eaton, 1994). 
We also previously demonstrated the ability of blue dex-
tran bulk-derivatized material to selectively bind 1251-
labeled albumin in the presence of increasing amounts of 
albumin-depleted human serum (Keogh et al., 1992). 
C. Tsai: Since dextran contains many hydroxyl (-OH) 
groups, have you performed any complement activation 
tests for blue dextran-derivatized surfaces? 
Authors: No formal tests have been performed for 
assessing complement activation. 
C. Tsai: Have you looked into any other index for 
measuring platelet activation such as thromboxane B2 or 
PF4 since the lack of platelet adhesion does not neces-
sarily mean the lack of platelet activation? 
Authors: It is absolutely correct that platelet adherence 
alone does not prove that platelets were not being acti-
vated. We have not yet carried out studies which meas-
ure platelet activation directly. 
C. Tsai: In your radiolabeled protein adsorption stud-
ies, what were the percentages of free iodide (i.e., label-
ing efficiency) in the 1251-labeled albumin and 1251-la-
beled fibrinogen solutions and will free iodide adsorb to 
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blue dextran-derivatized surfaces? 
Authors: We are confident that our radiolabeled protein 
solutions contained little or no free iodide since inclusion 
of large amounts of unlabeled Nal failed to change the 
amounts of surface associated 1251-labeled albumin or 
1251-labeled fibrinogen found adherent to derivatized or 
non-derivatized surfaces. 
C. Tsai: In your Chandler (1958) loop study, blue dex-
tran surface-derivatized tubing showed no clotting phe-
nomena (Table 2). Could you elaborate on this? 
Authors: At present, we have no firm explanation for 
the anti-thrombogenic activities of these surfaces. How-
ever, as shown previously (Keogh and Eaton, 1994), the 
blue dextran surface may activate antithrombin III in a 
heparin-like fashion. If so, this may be sufficient to 
explain the long-term anticoagulant effects which we 
have found . 
S.L. Goodman: Do you have any evidence on how 
well the blue dextran modified surfaces maintain their 
albumin binding affinity when in actual use? Does the 
blue dextran detach, degrade, or otherwise lose activity 
over time? If so, is there any toxicity or other problems 
associated with circulating or soluble blue dextran? 
Authors: Our best response to the durability question 
is that we do not know. As indicated above, we have 
not done the requisite long-term implantation or blood 
contact studies. However, we do suspect that the blue 
dextran will be relatively stable, even compared to hep-
arin-derivatized surfaces which can potentially be at-
tacked by heparinases known to be present in mammals. 
We believe the toxicity of blue dextran is unknown. 
S.L. Goodman: Do you have any direct measurements 
of the concentration of blue dextran which is on the 
derivatized surfaces, that is, other than the albumin 
adsorption measurements? If so, how does the surface 
concentration of blue dextran compare to the concentra-
tion of adsorbed albumin? Might the surface concentra-
tion of blue dextran be further optimized for reducing 
thrombogenicity and bacterial adherence? 
Authors: We have not yet attempted to measure the ac-
tual concentration of blue dextran which is on the deriv-
atized surfaces. However, we do believe that the sur-
face concentration of blue dextran or cibacron blue dye 
might be further optimized for reducing thrombogenicity 
and/or bacterial adherence. 
J.A. Chinn: Does blue dextran modification of poly-
urethanes affect their mechanical properties? 
Authors: As we reported (Keogh and Eaton, 1994), we 
saw no affect on the mechanical properties of blue 
dextran modified polyurethane. 
Albumin affinity biomaterial surfaces 
J.A. Chinn: Is blue dextran modified polyurethane 
chemically stable? Do samples contain leachable 
materials? 
Authors: The modified samples we tested did not ap-
pear to leach any material and, as mentioned above, we 
currently do not know the chemical in vivo stability of 
blue dextran modified polyurethane materials. 
J.A. Chinn: What affect did incubation of test samples 
with ethanol have on mechanical as well as surface prop-
erties of this material? Was material extracted from the 
polymer during incubation with ethanol, and, if so, how 
did this affect your results? 
Authors: We have not observed any significant effect 
of ethanol rinsing on the mechanical properties of the 
polyurethane materials. Depending on the length of ex-
traction, we sometimes observe some extracted material 
which we currently have not characterized. However, 
we believe the extracted material to be either processing 
aids Dow Chemical Co. may have added, low molecular 
weight urethane or possibly a combination of both. 
J.A. Chinn: It appears from Figure 6B that modified 
sub trate is very rough. How did surface roughness af-
fect your results? Did you account for the increase in 
surface area relative to unmodified polyurethane in your 
adsorption/elution calculations? 
Authors: We believe the observed roughness on sur-
faces of derivatized material is a drying artifact, one 
which may reflect the sites of primary "nucleation" of 
the acrylamide. We currently do not know of a way to 
calculate precisely the surface area of the modified 
surfaces. 
].A. Chinn: Protein adsorption is highly temperature 
and medium composition dependent. Can you extrap-
olate your results to physiological conditions, i.e., 
adsorption from whole blood at 37°C? 
Authors: We cannot extrapolate our room temperature 
protein binding studies to whole blood at 37°C, how-
ever, our blood loop results which were performed at 
37°C did provide favorable results. 
J.A. Chinn: Does human serum albumin (HSA) absorb 
into the dextran matrix? 
Authors: It is possible that some albumin may absorb 
into the dextran matrix. 
J.A. Chinn: You conclude that the increase in HSA 
binding observed with modified polyurethane is due to 
ligand-receptor interaction between the immobilized dye 
and the protein. How does your data indicate ligand-
receptor interaction rather than non-specific absorption 
and adsorption, followed by non-specific elution? 
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Authors: Once again, elution of pre-bound 125!-labeled 
albumin by solution phase unlabeled albumin and by 
solution phase blue dextran clearly indicates ligand 
binding. Furthermore, adsorbed albumin is not dis-
placed by dextran alone or proteins other than albumin. 
J.A. Chinn: Was elutability of fibrinogen measured? 
If fibrinogen and HSA were equally elutable, would that 
result effect your interpretation of the HSA binding 
data? 
Authors: Fibrinogen is elutable. However, this does 
not affect interpretation of our results but reflects the 
fact that hydrophilic surfaces, regardless of the function-
ali ties exposed, do not encourage the irreversible hydro-
phobic denaturation of bound proteins. 
J.A. Chinn: How do you explain the low retention of 
albumin by modified polyurethane given a Kd = w-7? 
Authors: We are not sure what you mean by low reten-
tion. It seems to us that retention of -1 monolayer af-
ter vigorous washing is pretty good. Incidentally, the 
Kd probably refers to non-cooperative binding of ciba-
cron blue by albumin, whereas it is quite possible that in 
the case of polymeric cibacron blue on dextran, the 
binding is cooperative. 
J.A. Chinn: Frautschi et al. (1987, personal communi-
cation) report enhanced albumin adsorption from buffer 
to alkylated polyurethanes, and subsequent low elutabili-
ty after incubation with SDS. They attribute high reten-
tion to strong ligand (alkyl residue)-receptor (albumin) 
interaction with native (not denatured) albumin. Fur-
ther, Munro et al. (1983) propose that adsorbed protein 
denatures, then desorbs. Subsequently, a native albumin 
molecule adsorbs to the freed alkyl residue. In contrast, 
Bohnert and Horbett (1986) interpret low elutability of 
adsorbed protein as denaturation. Which adsorption/elu-
tion mechanism is most consistent with your data? 
Authors: We would agree with Bohnert and Horbett 
(1986) that low elutability suggests surface denaturation. 
Such avid surface association does not indicate strong li-
gand-receptor interaction, particularly where low eluta-
bility extends to a denaturing agent such as SDS. 
J.A. Chinn: Sefton (1993) reports that hydrogel sur-
faces consume platelets, though few platelets are ob-
served adherent to the surface. Does dextran act as a 
hydrogel in your system? What does your data in Table 
I and Figure 4A indicate about non-adherent platelets? 
Authors: We agree that some hydrogel surfaces can 
consume platelets, but we disagree with the statement 
that all hydrogel surfaces consume platelets. In fact, we 
recently have reported on a sulphonated hydrogel surface 
which appeared not to consume platelets during a blood 
J.R. Keogh and J.W. Eaton 
loop experiment (Keogh et al., 1996). 
J.A. Chinn: Does low bacterial adherence indicated in 
Figure 7 represent a kinetic or an equilibrium effect? 
Authors: We are not sure if the observed decrease in 
bacterial adherence is attributable to a kinetic or an 
equilibrium effect, but suspect the latter. 
R.C. Eberhart: When surfaces are exposed to blood, 
plasma, or protein solution, non-specific binding takes 
place, i.e., binding not associated with the specific 
interaction between the ligand and the protein. Albumin 
and other proteins may have some affinity for dextran 
(Birkenmeier, 1984, personal communication). There-
fore, there may have been some degree of the albumin 
binding and retention due to non-specific association 
with the dextran and not the cibacron blue. Although 
the results of this paper are impressive, perhaps an 
instructive control surface would have been unmodified 
dextran. 
Authors: We have measured albumin binding to dex-
tran-derivatized surfaces (i.e., lacking the final cibacron 
blue modification) and found some binding. This bind-
ing does not show ligand specificity (i .e., selectivity for 
albumin) but is reversible. 
R.C. Eberhart: Immersing the sample into a protein 
solution is not a very good technique for protein adsorp-
tion studies as the air/water interface is known to dena-
ture protein. Therefore, as you lower your sample into 
the solution, you are passing it through a layer of dena-
tured protein which may or may not still have the ciba-
cron blue binding site intact. Therefore, as in Lang-
muir-Blodgett films, a film of denatured protein may be 
physically attached to your surface by this process inde-
pendent of any cibacron blue specific binding. There-
fore, in the future, I would suggest modifying your 
method of protein binding assays so that the adsorbed 
proteins do not have opportunity to denature and your 
surfaces have a chance to become fully hydrated prior to 
protein exposure. Based on this, do you believe that the 
protein binding results presented here are indicative of 
what might be seen clinically if your surface were to be 
used in cardiopulmonary bypass tubing, for example? 
Authors: Yes, we believe our protein binding results 
would be indicative of what might be seen clinically in 
cardiopulmonary bypass tubing. The main thrust of our 
binding studies was to investigate the reversible binding 
of the proteins under study. The results with albumin 
would, if anything, have been made less impressive if 
we had been accidentally adsorbing a layer of pre-dena-
tured albumin. But we agree that there are better ways 
to do these sorts of protein binding studies. 
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